Cannabinoid CB1 Receptor Neurons

Cannabinoid CB1 Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cannabinoid CB1 Receptor Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Receptor neurons</td>
</tr>
<tr>
<td class="label">Primary Receptor</td>
<td>CB1 (encoded by CNR1 gene)</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>Endocannabinoids (2-AG, anandamide)</td>
</tr>
<tr>
<td class="label">Signal Transduction</td>
<td>Gi/o protein-coupled inhibition of adenylate cyclase</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>Basal ganglia, cerebellum, hippocampus, cortex, hypothalamus</td>
</tr>
<tr>
<td class="label">Expression Pattern</td>
<td>Presynaptic terminals (axonal), some somatic</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Ligand</td>
<td>Full Name</td>
</tr>
<tr>
<td class="label">2-AG</td>
<td>2-Arachidonoylglycerol</td>
</tr>
<tr>
<td class="label">AEA</td>
<td>Anandamide (N-arachidonoylethanolamine)</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>CB1 Function</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Modulates LTPmechanisms/long-term-potentiation)/LTD, memory formati

Cannabinoid CB1 Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cannabinoid CB1 Receptor Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Receptor neurons</td>
</tr>
<tr>
<td class="label">Primary Receptor</td>
<td>CB1 (encoded by CNR1 gene)</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>Endocannabinoids (2-AG, anandamide)</td>
</tr>
<tr>
<td class="label">Signal Transduction</td>
<td>Gi/o protein-coupled inhibition of adenylate cyclase</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>Basal ganglia, cerebellum, hippocampus, cortex, hypothalamus</td>
</tr>
<tr>
<td class="label">Expression Pattern</td>
<td>Presynaptic terminals (axonal), some somatic</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Ligand</td>
<td>Full Name</td>
</tr>
<tr>
<td class="label">2-AG</td>
<td>2-Arachidonoylglycerol</td>
</tr>
<tr>
<td class="label">AEA</td>
<td>Anandamide (N-arachidonoylethanolamine)</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>CB1 Function</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Modulates LTPmechanisms/long-term-potentiation)/LTD, memory formation</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Regulates dopamine release, motor control</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Controls Purkinje cell function</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Regulates pyramidal neuron activity</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Modulates appetite, energy homeostasis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Dronabinol</td>
<td>HIV/AIDS anorexia, chemotherapy nausea</td>
</tr>
<tr>
<td class="label">Nabilone</td>
<td>Chemotherapy-induced nausea</td>
</tr>
<tr>
<td class="label">CBD</td>
<td>Epilepsy (Lennox-Gastaut, Dravet)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Rimonabant</td>
<td>Obesity (withdrawn)</td>
</tr>
<tr>
<td class="label">TM38837</td>
<td>Obesity/metabolic disorders</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Information Gained</td>
</tr>
<tr>
<td class="label">Radioligand binding ([3H]CP55,940)</td>
<td>Receptor density, affinity</td>
</tr>
<tr>
<td class="label">Immunohistochemistry</td>
<td>Cellular and subcellular localization</td>
</tr>
<tr>
<td class="label">In situ hybridization</td>
<td>CNR1 mRNA distribution</td>
</tr>
<tr>
<td class="label">Conditional knockout</td>
<td>Cell-type specific function</td>
</tr>
<tr>
<td class="label">Cre-lox recombination</td>
<td>Circuit-specific manipulation</td>
</tr>
</table>

Cannabinoid Cb1 Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

CB1 (cannabinoid receptor type 1) neurons represent one of the most abundant neuronal populations in the mammalian brain, expressing the highest density of G protein-coupled receptors (GPCRs) in the central nervous system. These neurons play a critical role in modulating synaptic transmission through retrograde signaling mechanisms, making them essential regulators of neural circuit function and plasticity. [@howlett2002]

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Molecular Biology

CB1 Receptor Structure

The CB1 receptor is a Class A GPCR encoded by the CNR1 gene located on chromosome 6q14-q15. The receptor consists of:

• Seven transmembrane domains spanning the postsynaptic membrane
• N-terminal extracellular domain involved in ligand binding
• C-terminal intracellular domain coupled to Gi/o proteins

Endocannabinoid Ligands

CB1 receptors are activated by endogenous cannabinoids (endocannabinoids):

Signaling Pathways

Upon activation, CB1 receptors couple to Gi/o proteins leading to:

Neurophysiology

Retrograde Synaptic Signaling

CB1 neurons mediate a unique form of retrograde synaptic transmission:

Circuit-Specific Functions

Clinical Significance

Epilepsy

The endocannabinoid system has bidirectional relationship with seizure activity:

• CB1 agonists and cannabidiol (CBD) have demonstrated antiepileptic properties
• FDA-approved CBD formulations (Epidiolex) for Lennox-Gastaut and Dravet syndromes
• Endocannabinoid dysfunction may contribute to seizure generation
• CB1 receptor expression is altered in epileptic hippocampus

Alzheimer's Disease

CB1 neurons play complex roles in AD pathogenesis:

• CB1 receptor loss correlates with disease progression in AD brains
• Endocannabinoid signaling modulates amyloid-beta (Aβ) toxicity
• CB1 agonism may provide neuroprotection through anti-inflammatory mechanisms
• Memory deficits in AD may involve impaired CB1-mediated synaptic plasticity

Parkinson's Disease

In PD, CB1 receptors interact with dopaminergic systems:

• CB1/D2 receptor heteromers have been identified in the striatum
• CB1 antagonists may improve motor function in PD models
• Endocannabinoid levels are elevated in PD patients
• CB1 modulation affects levodopa-induced dyskinesias

Multiple Sclerosis

CB1 neurons contribute to neuroinflammation regulation:

• CB1 activation reduces inflammatory cytokine production
• Myelin repair may be modulated by endocannabinoid signaling
• Spasticity is reduced by CB1 agonists (THC, nabilone)

Therapeutic Targeting

CB1 Agonists

CB1 Antagonists

Future Directions

• Peripherally-restricted CB1 antagonists for metabolic diseases
• CB1 positive allosteric modulators for neuroprotection
• FAAH/MAGL inhibitors to elevate endocannabinoid levels
• CB1-CB2 heteromer-selective compounds
• Endocannabinoid System
• Dopamine D2 Receptor Neurons
• [GABAergic Neurons](/cell-types/gabaergic-neurons)
• Hippocampal CA1 Neurons
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• CNR1 Gene
• CB1 Protein

Background

The study of Cannabinoid Cb1 Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Neuroanatomy

Regional Distribution

CB1 receptor expression follows a characteristic pattern across brain regions:

Highest Expression:

• Cerebellum (molecular layer interneurons)
• Basal ganglia (striatum, globus pallidus)
• Hippocampus (CA1, CA3 strata radiatum and lacunosum-moleculare)
• Cerebral cortex (layers II-III, V-VI)

• Hypothalamus (preoptic area, paraventricular nucleus)
• Amygdala (central, basolateral nuclei)
• Thalamus (mediodorsal, intralaminar nuclei)

• Brainstem (dorsal raphe, locus coeruleus)
• Spinal cord (dorsal horn)

Cellular Localization

• Presynaptic terminals: Primary location on axon terminals
• Somatic: Lower density on cell bodies
• Dendritic: Present on dendritic shafts and spines
• Glial: Astrocytic expression also documented

Neurodevelopment

Developmental Expression Pattern

CB1 receptor expression develops progressively:

• - Myelination**: Influences oligodendrocyte differentiation

Research Methods

Experimental Approaches

Animal Models

• CNR1-/- mice: Constitutive knockout, developmental compensation
• CNR1flox/flox mice: Conditional knockout flexibility
• ** reporter mice | Circuit mapping |
• **Disease models | AD, PD, epilepsy models |

Neurodegeneration Mechanisms

Amyloid-Beta Interaction

• Aβ oligomers reduce CB1 receptor density
• CB1 activation reduces Aβ-induced toxicity
• FAAH inhibition (elevating AEA) protects against Aβ

Tau Pathology

• Tau pathology correlates with CB1 loss
• CB1 agonists may reduce tau phosphorylation
• Endocannabinoid dysregulation in tauopathies

Neuroinflammation

• CB1 activation has anti-inflammatory effects
• Reduces microglial activation
• Modulates cytokine production

Oxidative Stress

• Endocannabinoids have antioxidant properties
• CB1 agonists protect against oxidative damage
• Mitochondrial CB1 contributes to neuroprotection

Pathway Diagram

The following diagram shows the key molecular relationships involving Cannabinoid CB1 Receptor Neurons discovered through SciDEX knowledge graph analysis: